PseudoSimulations-class: This is a class which captures the trial simulations from designs using pseudo model. The design for DLE only responses and model from `ModelTox` class object. It contains all slots from `GeneralSimulations` object. Additional slots fit and stopReasons compared to the general class `GeneralSimulations`.

Description

This is a class which captures the trial simulations from designs using pseudo model. The design for DLE only responses and model from ModelTox class object. It contains all slots from GeneralSimulations object. Additional slots fit and stopReasons compared to the general class GeneralSimulations.

Arguments

Slots

fit: list of the final values. If samples are involved, these are the final fitted values. If no samples are involved, these are included the final modal estimates of the model parameters and the posterior estimates of the probabilities of the occurrence of a DLE.

FinalTDtargetDuringTrialEstimates

the vector of all final estimates (the last estimate of) the TDtargetDuringTrial at the end of each simultaions/when each trial stops

FinalTDtargetEndOfTrialEstimates

vector of all final estimates or the last estimate of the TDtargetEndOfTrial when each trial stops

FinalTDtargetDuringTrialAtDoseGrid

vector of the dose levels at dose grid closest below the final TDtargetDuringTrial estimates

FinalTDtargetEndOfTrialAtDoseGrid

vector of the dose levels at dose grid closest below the final TDtargetEndOfTrial estimates

FinalTDEOTCIs

is the list of all 95% credibility interval of the final estimates of the TDtargetEndOfTrial

FinalTDEOTRatios

is the vector of the ratios of the CI, the raatio of the upper to the lower 95% credibility intervals of the final estimates of the TDtargetEndOfTrial

FinalCIs

list of all the final 95% credibility intervals of the TDtargetEndofTrial estimates or of the final optimal dose estimates when DLE and efficacy responses are incorporated after each simulations

FinalRatios

vector of all the final ratios, the ratios of the upper to the lower 95% credibility interval of the final estimates of the TDtargetEndOfTrial or of the final optimal dose estiamtes (when DLE and efficacy responses are incorporated) after each simulations

stopReasons

todo: add slot description